Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform
Por:
Volkman, HR, De Munter, L, Nguyen, JL, Tran, TMP, Mitratza, M, Marques, C, Choi, L, Valluri, S, Yang, JY, Antón, A, Casas, I, Conde-Sousa, E, Drikite, L, Grüner, B, Icardi, G, Ten Kate, GL, Martin, C, Mira-Iglesias, A, Orrico-Sánchez, A, Otero-Romero, S, Rohde, G, Jodar, L, Mclaughlin, JM and Bollaerts, K
Publicada:
11 feb 2026
Resumen:
Background While multiple studies report that the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (BNT162b2 XBB vaccine) is effective in preventing COVID-19 hospitalisation and death, effectiveness beyond six months remains unexplored. Methods We extended our previous study of BNT162b2 XBB vaccine effectiveness (VE) to evaluate durability against JN.1-related hospitalisation up to 46 weeks since dose using the id.DRIVE platform across Europe. This multi-country, multi-centre test-negative case-control study assessed the effectiveness and durability of the BNT162b2 XBB vaccine in preventing JN.1-associated hospitalisation among adults with severe acute respiratory infection between October 2023 and August 2024. Each case was matched with up to four controls by symptom onset date and study site. Multivariable analyses were adjusted for symptom onset date, age, sex, number of chronic conditions, and influenza vaccination receipt. Results Among 827 test-positive cases and 2232 test-negative controls, protection against hospitalisation was sustained from two to <30 weeks since dose, with evidence of significant waning thereafter. VE was 64.5% (95% CI: 56.6; 71.0) at two to <30 weeks, and 4.9% (95% CI: -30.3; 30.7) at 30 to <46 weeks. Conclusion Despite the vaccine target not matching the predominant subvariant, BNT162b2 XBB vaccine protected against JN.1-related hospitalisation for up to 30 weeks. Protection against hospitalisation was non-significant after 30 weeks since dose, potentially due to further shift in circulating SARS-CoV-2 strains and/or waning immunity. Given the high COVID-19 activity in Europe during summer 2024, an additional vaccination after six months is warranted for those at risk of COVID-19 hospitalisation to maintain year-round protection.
Filiaciones:
Volkman, HR:
Pfizer Inc, New York, NY 10001 USA
De Munter, L:
P95 Clin & Epidemiol Serv, Leuven, Belgium
Nguyen, JL:
Pfizer Inc, New York, NY 10001 USA
Tran, TMP:
P95 Clin & Epidemiol Serv, Leuven, Belgium
Mitratza, M:
P95 Clin & Epidemiol Serv, Leuven, Belgium
Marques, C:
Pfizer Inc, New York, NY 10001 USA
Choi, L:
Pfizer Inc, New York, NY 10001 USA
Valluri, S:
Pfizer Inc, New York, NY 10001 USA
Yang, JY:
Pfizer Inc, New York, NY 10001 USA
Antón, A:
Univ Autonoma Barcelona, Hosp Univ Vall Hebron, Vall Hebron Inst Recerca VHIR, Microbiol Dept, Barcelona, Spain
:
Hosp Univ Germans Trias i Pujol, Carretera Canyet, Badalona, Barcelona, Spain
Conde-Sousa, E:
P95 Clin & Epidemiol Serv, Leuven, Belgium
Drikite, L:
P95 Clin & Epidemiol Serv, Leuven, Belgium
Grüner, B:
Univ Hosp Ulm, Dept Internal Med 3, Div Infect Dis, Ulm, Germany
Icardi, G:
IRCCS Policlin San Martino Hosp, Ctr Interuniv Ric Influenza & Altre Infezioni, Genoa, Italy
Ten Kate, GL:
Univ Ziekenhuis Antwerpen, Edegem, Belgium
Martin, C:
Le Ctr Hosp Univ St Pierre, Brussels, Belgium
Mira-Iglesias, A:
FISABIO Publ Hlth, Vaccine Res Dept, Valencia, Spain
Inst Salud Carlos II, Biomed Res Consortium Epidemiol & Publ Hlth CIBER, Madrid, Spain
Orrico-Sánchez, A:
FISABIO Publ Hlth, Vaccine Res Dept, Valencia, Spain
Inst Salud Carlos II, Biomed Res Consortium Epidemiol & Publ Hlth CIBER, Madrid, Spain
Catholic Univ Valencia, Valencia, Spain
Otero-Romero, S:
Univ Autonoma Barcelona, Hosp Univ Vall Hebron, Vall Hebron Inst Recerca VHIR, Prevent Med & Epidemiol Dept, Barcelona, Spain
Univ Autonoma Barcelona, Vall Hebron Inst Recerca VHIR, Ctr Esclerosis Multiple Catalunya Cemcat, Hosp Univ Vall Hebron,Dept Neurol Neuroimmunol, Barcelona, Spain
Rohde, G:
Goethe Univ Frankfurt, Univ Hosp, Dept Resp Med, Med Clin 1, Frankfurt, Germany
Jodar, L:
Pfizer Inc, New York, NY 10001 USA
Mclaughlin, JM:
Pfizer Inc, New York, NY 10001 USA
Bollaerts, K:
P95 Clin & Epidemiol Serv, Leuven, Belgium
Green Submitted, gold
|